Therefore, a combination of CD19-CAR-NK cells possessing ADCC with the anti-CD20 monoclonal antibody Rituximab may provide a treatment option for aggressive relapsed CD19+ and CD20+ B-ALL. Here, CD19 is linked to acute lymphoblastic leukemia.